Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Predictive Oncology Inc (NQ: POAI )

3.220 -0.080 (-2.42%)
Streaming Delayed Price Updated: 2:14 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Predictive Oncology Inc

< Previous 1 2 3 Next >
Predictive Oncology Announces Appointment of Oncology Translational Research Leader Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board
From Predictive Oncology Inc.
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Integra Therapeutics Collaborate to Advance Gene Therapy
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy
From Predictive Oncology Inc.
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Collaborates to Leverage AI for New Cancer Drugs, Announces 2022 Results
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update
From Predictive Oncology Inc.
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Key Partnership, Declares Dividend
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common Stock
From Predictive Oncology Inc.
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Engages with Leading IR Consultant to Implement Comprehensive IR Effort
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations Partner
Comprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and... 
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Issues Letter to Shareholders
From Predictive Oncology Inc.
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Talks New Cvergenx Partnership During Proactive Interview
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Updates Shareholders, Provides Company Overview and Plans for Future
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Cvergenx Inc. to Collaborate in Novel Approach to Personalized Radiotherapy and Drug Discovery
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence
From Predictive Oncology Inc.
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names New Chief Business Officer
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Program to Partner Academic, Research Institutions to Assist with Drug-Discovery Initiatives
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Predictive Oncology launches ACE program to partner with academic and research institutions to advance their drug discovery initiatives
First round of applications due March 31, 2023 
From Predictive Oncology Inc.
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Seasoned Veteran as New Chief Business Officer
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer
From Predictive Oncology Inc.
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Computational Biology Pioneer as New Scientific Advisory Board Member
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Pioneer of Computational Biology Joins the Scientific Advisory Board of Predictive Oncology
From Predictive Oncology Inc.
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Expands Scientific Advisory Board to Appoint Genomics Expert
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Distinguished Innovator in Genomics Joins the Scientific Advisory Board of Predictive Oncology
From Predictive Oncology Inc.
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Board Member
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property Product Safety
Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors
From Predictive Oncology Inc.
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q3 Financial Report, Corporate Update
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Predictive Oncology Reports Third Quarter Financial Results
From Predictive Oncology Inc.
Via GlobeNewswire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Appoints Key Life Sciences Thought Leader to Its Board
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
David S. Smith appointed to the Board of Directors of Predictive Oncology
Leading authority on the therapeutic use of human tissues and cells 
From Predictive Oncology Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.